1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides an overview of the Kidney Cancer (Oncology) pipeline landscape.
Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kidney Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 20, 162, 156, 2, 12, 101, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 14, 8, 1, 16 and 1 molecules, respectively.
Kidney Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Kidney Cancer - Overview
- Kidney Cancer - Therapeutics Development
- Kidney Cancer - Therapeutics Assessment
- Kidney Cancer - Companies Involved in Therapeutics Development
- Kidney Cancer - Drug Profiles
- Kidney Cancer - Dormant Projects
- Kidney Cancer - Discontinued Products
- Kidney Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by 4D Pharma Plc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Aadi Bioscience Inc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by ABL Bio Inc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Acepodia Biotech Inc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Acrotech Biopharma LLC, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Actuate Therapeutics Inc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by ADC Therapeutics SA, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Affimed GmbH, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Agenus Inc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by AIM ImmunoTech Inc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Akeso Inc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Alkermes Plc, H1 2020
- Kidney Cancer (Renal Cell Cancer) - Pipeline by Alligator Bioscience AB, H1 2020
List of Figures
- Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma Plc
- 4SC AG
- Aadi Bioscience Inc
- AbbVie Inc
- ABL Bio Inc
- Acepodia Biotech Inc
- Acrotech Biopharma LLC
- Actuate Therapeutics Inc
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Adlai Nortye Biopharma Co Ltd
- Advenchen Laboratories LLC
- Affimed GmbH
- Affitech A/S
- Agenus Inc
- AIM ImmunoTech Inc
- Akeso Inc
- Alkermes Plc
- Alligator Bioscience AB
- Allogene Therapeutics Inc
- Almac Discovery Ltd
- AlphaMab Co Ltd
- Alphamab Oncology
- Altor Bioscience LLC
- ALX Oncology Inc
- Ambrx Inc
- Amgen Inc
- Amphivena Therapeutics Inc
- Anaveon AG
- Andes Biotechnologies
- Anew Oncology Inc
- Anhui Anke Biotechnology (Group) Co Ltd
- Antengene Corp
- AntiCancer Inc
- Apcure SAS
- APEIRON Biologics AG
- Apexigen Inc
- Apollomics Inc
- Apotex Inc
- Aprea Therapeutics AB
- Aravive Inc
- Arcus Biosciences Inc
- Argenx SE
- Arrowhead Pharmaceuticals Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Bavarian Nordic A/S
- Bayer AG
- BeiGene Ltd
- Beijing Eastern Biotech Co Ltd
- Beijing Foreland Pharma Co Ltd
- Beijing Kawin Technology Share-Holding Co Ltd
- Benhealth Biopharmaceutical (Shenzhen) Co Ltd
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- Biocad
- Biocon Ltd
- Biohaven Pharmaceutical Holding Company Ltd
- BioIntegrator Ltd
- Bionomics Ltd
- BioNTech SE
- Biotest AG
- BioXpress Therapeutics SA
- Boehringer Ingelheim International GmbH
- Boryung ViGenCell Inc
- Boston Biomedical Inc
- BridgeBio Pharma Inc
- Bristol-Myers Squibb Co
- Byondis BV
- Calithera Biosciences Inc
- Canget BioTekpharma LLC
- CASI Pharmaceuticals Inc
- Celldex Therapeutics Inc
- Celyad Oncology
- Centurion BioPharma Corp
- Checkpoint Therapeutics Inc
- Chineo Med Beijing Co Ltd
- Chipscreen Biosciences Ltd
- Cleveland BioLabs Inc
- Clovis Oncology Inc
- COARE Biotechnology Inc
- CoImmune Inc
- Constellation Pharmaceuticals Inc
- Corvus Pharmaceuticals Inc
- CRISPR Therapeutics AG
- CSPC Pharmaceutical Group Ltd
- CureLab Oncology Inc
- Cytocom Inc
- Daiichi Sankyo Co Ltd
- Debiopharm International SA
- DevaCell Inc
- Dr. Reddy's Laboratories Ltd
- Dragonfly Therapeutics Inc
- Ecrins Therapeutics SAS
- eFFECTOR Therapeutics Inc
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- EnGeneIC Ltd
- Enochian Biosciences Inc
- EpimAb Biotherapeutics Inc
- Epizyme Inc
- Epygen Biotech Pvt Ltd
- Ervaxx Ltd
- Esanex Inc
- Esperance Pharmaceuticals Inc
- Evaxion Biotech ApS
- Evelo Biosciences Inc
- Exelixis Inc
- EXUMA Biotech Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Five Prime Therapeutics Inc
- Fresenius SE & Co KGaA
- GEMoaB Monoclonals GmbH
- Gene Techno Science Co Ltd
- Genentech Inc
- Geneos Therapeutics Inc
- Genmab AS
- Genocea Biosciences Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GLG Pharma SA
- Glycotope GmbH
- Guangzhou Hanghua Bio Pharmaceutical Technology Co
- Handa Pharmaceuticals LLC
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- HEC Pharm Co Ltd
- Helixmith Co Ltd
- Hengenix Biotech Inc
- Hibiskus Biopharma Inc
- Horizon Therapeutics Plc
- Hualan Biological Engineering Inc
- Hutchison MediPharma Ltd
- Idera Pharmaceuticals Inc
- Ikena Oncology Inc
- Immune Pharmaceuticals Inc
- Immune System Key Ltd
- Immune Therapeutics Inc
- ImmuneSensor Therapeutics Inc
- Immunicum AB
- ImmunityBio Inc
- Immunocore Ltd
- ImmunoGen Inc
- Immunomedics Inc
- Immunomet Therapeutics Inc
- Incyte Corp
- Infinity Pharmaceuticals Inc
- Inhibrx Inc
- Inmune Bio Inc
- Innate Pharma SA
- InnoCare Pharma Ltd
- Innovative Cellular Therapeutics Co Ltd
- Innovent Biologics Inc
- InSight Biopharmaceuticals Ltd
- InteRNA Technologies BV
- IO Biotech ApS
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Jounce Therapeutics Inc
- JSK Therapeutics Inc
- Jubilant Therapeutics Inc
- Karyopharm Therapeutics Inc
- Kinnate Biopharma Inc
- Komipharm International Co Ltd
- Konruns Pharmaceutical Co Ltd
- Kuda Therapeutics Inc
- Kymab Ltd
- Kyowa Kirin Co Ltd
- Lantern Pharma Inc
- Lead Discovery Center GmbH
- Lipac Oncology LLC
- Lotus Pharmaceutical Co Ltd
- Luye Pharma Group Ltd
- Lycera Corp
- MacroGenics Inc
- Mana Therapeutics Inc
- Mantis Therapeutics BV
- Marino Biotechnology Co Ltd
- MaxiVAX SA
- MdBioLab
- MediciNova Inc
- MedPacto Inc
- Merck & Co Inc
- Merck KGaA
- Mersana Therapeutics Inc
- Metagone Biotech Inc
- Metis Precision Medicine
- Midissia Therapeutics Inc
- Millennium Pharmaceuticals Inc
- Mirati Therapeutics Inc
- Miyarisan Pharmaceutical Company Ltd
- Moderna Inc
- Modulation Therapeutics Inc
- Molecular Partners AG
- Molecular Templates Inc
- Moleculin Biotech LLC
- Multitude therapeutics Inc
- MultiVir Inc
- Mycenax Biotech Inc
- NanoCarrier Co Ltd
- Nanology LLC
- NantKwest Inc
- Nektar Therapeutics
- Neoleukin Therapeutics Inc
- NeoTX Therapeutics Ltd
- Novartis AG
- Ocellaris Pharma Inc
- Omeros Corp
- OncBioMune Pharmaceuticals Inc
- OncoImmune Inc
- Oncology Venture A/S
- Oncology Venture U.S. Inc
- Oncolys BioPharma Inc
- Oncopeptides AB
- Oncorena AB
- Oncovir Inc
- Ono Pharmaceutical Co Ltd
- Orion Corp
- Orpheus Therapeutics Inc
- Pact Pharma Inc
- Peptron Inc
- Pfizer Inc
- Pharma Mar SA
- PharmAbcine Inc
- Pharmicell Co Ltd
- Philogen SpA
- Phosplatin Therapeutics LLC
- Poseida Therapeutics Inc
- Prestige BioPharma Pte Ltd
- PsiOxus Therapeutics Ltd
- QED Therapeutics Inc
- Qilu Puget Sound Biotherapeutics Corp
- Qu Biologics Inc
- Quadriga BioSciences Inc
- Qualigen Therapeutics Inc
- RAPT Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- RemeGen Ltd
- Replimune Ltd
- RevImmune SAS
- Rexahn Pharmaceuticals Inc
- Richter Gedeon Nyrt
- Rizen (Suzhou) Biosciences Co Ltd
- Ryvu Therapeutics SA
- Samyang Biopharmaceuticals Corp
- Sanofi
- Sapphire Biotech Inc
- Sareum Holdings Plc
- Scancell Holdings Plc
- Scholar Rock Inc
- Schrodinger LLC
- Seneca Therapeutics Inc
- Seven and Eight Biopharmaceuticals Corp
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shattuck Labs Inc
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Shionogi & Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Sichuan Huiyang Life Science and Technology Corp
- Sichuan Sinovation Bio-technology Co Ltd
- SignalRx Pharmaceuticals Inc
- Sillajen Biotherapeutics
- Sinocelltech Ltd
- Sonoval LLC
- Sorrento Therapeutics Inc
- Sotio AS
- Spring Bank Pharmaceuticals Inc
- Sprint Bioscience AB
- Starpharma Holdings Ltd
- Steba Biotech SA
- Sumitomo Dainippon Pharma Co Ltd
- Suntec Medical (Taiwan) Inc
- Surface Oncology Inc
- Suzhou Kintor Pharmaceutical Inc
- Suzhou Stainwei Biotech Inc
- Syndax Pharmaceuticals Inc
- Syndivia SAS
- Synermore Biologics Co Ltd
- T-Cure Bioscience Inc
- Tactical Therapeutics Inc
- Taiho Oncology Inc
- Taiho Pharmaceutical Co Ltd
- Tarus Therapeutics Inc
- Telix Pharmaceuticals Ltd
- Tempest Therapeutics Inc
- Teon Therapeutics Inc
- TheraPten Biosciences Inc
- Torque Therapeutics Inc
- Turning Point Therapeutics Inc
- TVAX Biomedical Inc
- Tyme Technologies Inc
- UbiVac LLC
- Vaccibody AS
- Vault Pharma Inc
- Vaxiion Therapeutics Inc
- Veana Therapeutics LLC
- Vyriad Inc
- X4 Pharmaceuticals Inc
- Xbrane Biopharma AB
- Xcovery Holding Co LLC
- Xencor Inc
- Xspray Pharma AB
- Xynomic Pharmaceuticals Holdings Inc
- Y-mAbs Therapeutics Inc
- Yuhan Corp
- Zelluna Immunotherapy AS
- Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
